Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Multiple Sclerosis (Aug 2016)

Posted by Matt Breese on Aug 12, 2016

Find me on:

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for MS treatments shows some differences in coverage across major payer channels. Commercial and health exchange market access is fairly similar, while Medicare formularies are the most restrictive, with less than 10% of lives unrestricted.


Source: MMIT data as of Q3 2016

Trends: One trend is the expanded physician focus on programs that help detect early MS symptoms in patients. New research reveals that early MS detection improves patient chances to avoid full-blown MS by 33%. For pharmaceutical manufacturers in the space, protecting drug patents is critical. Recent engagements with MS doctors shows how HCPs perceive branded and generic products in this class.

To read the full Reality Check on MS treatments with key findings on clinical characteristics, MS drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing